Over the years, scientist believed that aging was a functional decline caused by the accumulation of random molecular damage in organisms. They also thought that aging could not be prevented. However, the development of the hyperfunction theory has brought a sudden death to this old belief. According to the new theory, aging is the continuation of growth. Signaling pathways facilitate this process. An example of such pathway is Target of Rapamycin (TOR). Using TOR-centric models, scientists have predicted that rapamycin and other similar products could be used to treat aging in humans and prevent many other diseases. According to scientists, the right dosage of Rapamycin can be used to prolong human’s lifespan. Read more on templeofthecave.com
Today, various analogs of rapamycin have created headlines. One of them is the Evirolimus (RAD001). The findings of the study about of the drug resulted in hundreds of sensational captions. Some of them referred to Evirolimus as the ‘fountain of youth.’ The study found that the drug causes a delay in the effects of aging. It also improves the health of older adults. This information was originally mentioned on Impact Journals as explained in the link below http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=3740
Rapamycin is not new in the medical world. The first versions of the drug, Sirolimus and Rapamune, were approved for clinical use in 2006. The drug could treat many diseases, including cancer, autoimmunity, metabolic disorders, and cardiovascular diseases. It was also effective on diseases resulting from old age such as Alzheimer’s and osteoporosis.
When the drugs were released in 2006, they were declared safe enough to be used by transplant patients for many years. The drug’s safety has enabled scientist to study its pharmacokinetics on healthy volunteers. According to the researchers, the drug transforms the immunity of an aged individual to an ‘infant-type’ immunity. This way, it rejuvenates one’s immunity.
While summarizing his paper, Mikhail V. Blagosklonny, the editor-in-chief of Oncotarget, notes that the correct selection of doses during clinical trials of the drugs will result in the maximal extension of lifespan. It will also improve human’s aging tolerance. Its use should also be combined with other medical progress that helps in improving one’s aging tolerance like bypass surgery. Mikhail advises gerontologist to revert their studies from how free radicals and random molecular damage accumulation cause aging to how they cause post-aging syndromes. Such studies will make it easier for medical experts to fight the syndrome when advancement in rapamycin has enabled humans to reach post-aging age. View his LinkedIn profile
About Mikhail Blagosklonny
Mikhail Blagosklonny is a renowned oncologist. The scientist is a professor of oncology at the prestigious Roswell Park Cancer Institute where he also conducts research on aging and cancer. Mikhail is a proud alumnus of St. Petersburg’s First Pavlov State Medical University. Previously, he worked for Ordway Research Institute as a senior scientist and the New York Medical College as an associate professor. This information was originally mentioned on Classroom Voices as outlined in this link https://classroomvoices.org/understanding-oncology-through-mikhail-blagosklonny/